Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Elixinol WellnessASX:EXL Cash-to-Debt is 0.40 as of Dec. 2025, which is 87% below its 10-year median of 2.99. The stock has 7 warning signs investors should review. Among 979 Drug Manufacturers companies, Elixinol Wellness ranks worse than 65.88% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Elixinol Wellness's cash to debt ratio for the quarter that ended in Dec. 2025 was 0.40.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Elixinol Wellnesscouldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for Elixinol Wellness's Cash-to-Debt or its related term are showing as below:
ASX:EXL'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.4 Med: 2.99 Max: 171.69
Current: 0.4
During the past 8 years, Elixinol Wellness's highest Cash to Debt Ratio was 171.69. The lowest was 0.40. And the median was 2.99.
ASX:EXL's Cash-to-Debt is ranked worse than 65.88% of 979
companies
in the Drug Manufacturers industry
Industry Median: 0.97
vs ASX:EXL: 0.40
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Elixinol Wellness Cash-to-Debt Related Terms
Elixinol Wellness Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Elixinol Wellness's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Elixinol Wellness's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elixinol Wellness Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Elixinol Wellness's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Elixinol Wellness's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elixinol Wellness (ASX:EXL) has a Cash-to-Debt of 0.40 as of Dec. 2025. This is 87% below median its historical median of 2.99. Over the past decade, Elixinol Wellness' Cash-to-Debt has ranged from 0.40 to 171.69. According to the industry distribution chart, Elixinol Wellness ranks #645 out of 979 companies in the Drug Manufacturers industry, placing it in the top 65.9%.
Is Elixinol Wellness' Cash-to-Debt too high?
Elixinol Wellness' current Cash-to-Debt of 0.40 is 87% below median its 10-year median of 2.99. Over the past 10 years, this metric has ranged from a low of 0.40 to a high of 171.69. The Drug Manufacturers industry median Cash-to-Debt is 0.97. Elixinol Wellness' value of 0.40 is 58.8% below this industry median. Based on the distribution chart, Elixinol Wellness ranks #645 out of 979 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does Elixinol Wellness' Cash-to-Debt compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Elixinol Wellness ranks #645 out of 979 companies for Cash-to-Debt. This places Elixinol Wellness in the lower half of its industry. The industry median Cash-to-Debt is 0.97. Elixinol Wellness' value of 0.40 is 58.8% below this benchmark. Historically, Elixinol Wellness' own Cash-to-Debt has ranged from 0.40 to 171.69 over the past decade. While the company's 10-year median is 2.99 vs. the industry median of 0.97, Elixinol Wellness has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 0.97, based on 979 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Elixinol Wellness's current Cash-to-Debt of 0.40 is 58.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 0.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elixinol Wellness's current Cash-to-Debt is 0.40, which is 87% below median its own 10-year median of 2.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elixinol Wellness stock overvalued right now?
Based on GuruFocus' analysis, Elixinol Wellness (ASX:EXL) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.02, compared to a current price of A$0.01 — trading 60% below its estimated fair value. The current Cash-to-Debt is 0.40, which is 87% below median its 10-year median of 2.99 and 58.8% below the Drug Manufacturers industry median of 0.97. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Elixinol Wellness (ASX:EXL), the current Cash-to-Debt is 0.40 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Elixinol Wellness Ltd is engaged in the hemp industry, innovating, marketing, and selling hemp-derived nutraceutical, cosmetic, and food products. It operates in the three operating segments of the Americas, Australia, Rest of the World regions of which key revenue is derived from the Australia segment. The Australia segment includes the results from operations of Elixinol Wellness (Byron Bay) Pty Ltd and The Sustainable Nutrition Group Pty Ltd and its subsidiaries. It derives maximum revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EXL has been successfully added to your 
